Differentiated Thyroid Cancer and the use of recombinant human thyroid-stimulating hormone
Material type:
TextSeries: Staff Publications- Fitzpatrick, David ; Staff Publications- Moriarty, MichaelDDC classification: - PUBLICATIONS ARCHIVE MORI
| Item type | Current library | Home library | Shelving location | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|---|
| 2 Week Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | PUBLICATIONS ARCHIVE MORI (Browse shelf(Opens below)) | Available | 39015000015522 |
Total holds: 0
Browsing St. Luke’s Radiation Oncology Network Dublin shelves, Shelving location: AR Close shelf browser (Hides shelf browser)
| PUBLICATIONS ARCHIVE LABS Decrease in numbers of glandular cell groups in post-LLETZ liquid-based cytology preparations. | PUBLICATIONS ARCHIVE MCAR Contraindications to cisplatin based chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa. | PUBLICATIONS ARCHIVE MCDE Acute Colonic Obstruction Due to Benign Prostatic Hypertrophy | PUBLICATIONS ARCHIVE MORI Differentiated Thyroid Cancer and the use of recombinant human thyroid-stimulating hormone | PUBLICATIONS ARCHIVE MORI Bystander and other delayed effects and multi-organ involvement and failure following high dose exposure to ionising radiation. | PUBLICATIONS ARCHIVE MORI Radiotherapy and the potential exploitation of bystander effects | PUBLICATIONS ARCHIVE MORI Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model |
There are no comments on this title.
Log in to your account to post a comment.